Treatment with BCR‐ABL tyrosine kinase inhibitors (TKIs) is the standard of care for patients with chronic myeloid leukemia, however evidence indicates these compounds may have cardiovascular side‐effects. This study sought to determine if ex vivo exposure of human adipose arterioles to the BCR‐ABL TKIs imatinib and nilotinib causes endothelial dysfunction.

中文翻译：

---

BCR-ABL 酪氨酸激酶抑制剂促进人类微血管系统扩张器表型的病理变化。

BCR-ABL 酪氨酸激酶抑制剂 (TKI) 治疗是慢性粒细胞白血病患者的标准治疗，但有证据表明这些化合物可能具有心血管副作用。本研究旨在确定人体脂肪小动脉离体暴露于 BCR-ABL TKI 伊马替尼和尼罗替尼是否会导致内皮功能障碍。